Clinical trials: HCC - Hepatocellular Carcinoma
Neoplastic Disease, Solid Tumor
Indocyanine Green (ICG) Guided Tumor Resection
This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is critical for achieving a cure.
- Trial name
- NCT04084067
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- St. Jude Children's Research Hospital
Hepatocellular Carcinoma (HCC)
Artificially Intelligent Model for Accurate Detection of HCC
Purpose: Integrating comprehensive information on hepatocellular carcinoma (HCC) is essential to improve its early detection. The investigators aimed to develop a model with multi-modal features (MMF) using artificial…
- Trial name
- NCT06637059
- Testing
- observational study
- Where
- China
- Volunteers
- 1,092 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma (HCC)
Role of Long Noncoding RNA LINC01134 in Metastasis of Hepatitis C Virus-related Hepatocellular Carcinoma
LINC01134, a novel lncRNA, has received increasing attention in cancer research, particularly in hepatocellular carcinoma (HCC).
- Trial name
- NCT07130474
- Volunteers
- 50 people
- Sponsor
- Sohag University
Post-hepatectomy Liver Failure, Hepatocellular Carcinoma
Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction
The goal of this in-silico clinical trial is to learn about the usability and clinical effectiveness of an interpretable deep learning framework (VAE-MLP) using counterfactual explanations and layerwise relevance propagation for…
- Conditions
- Post-hepatectomy Liver Failure, Hepatocellular Carcinoma, Artificial Intelligence
- Trial name
- NCT06031818
- Testing
- The explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation, The model prediction, The model prediction and the explanation of deep learning framework (VAE-MLP) , including counterfactual explanations and layerwise relevance propagation
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Maastricht University
Hepatocellular Carcinoma, Radioembolization
Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most-common cancer worldwide and the second most-common cause of cancer mortality. Liver resection is the first-line curative treatment for huge HCC.
- Trial name
- NCT02724436
- Testing
- TACE, radioembolization with Y-90
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Adenoma, Liver Cell
Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry
The purpose of this study is to determine whether a treatment with Therasphere which is optimized is more efficient compared to a standard treatment for patients suffering from hepatocellular carcinomas.
- Trial name
- NCT02582034
- Testing
- Optimized Internal Radiation Therapy, Standard Internal Radiation Therapy
- Where
- 4 sites in France
- Volunteers
- 56 people
- Sponsor
- Center Eugene Marquis
Hepatocellular Carcinoma
Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
In India, majority of our patients have advanced hepatocellular carcinoma (HCC) at presentation and hence are unsuitable for the available curative treatment options. In such patients the treatment options are mainly palliative.
- Trial name
- NCT02240771
- Testing
- Transarterial chemotherapy, Oral chemotherapy
- Where
- India
- Volunteers
- 124 people
- Sponsor
- All India Institute of Medical Sciences
HepatoCellular Carcinoma
Hepatic Arteriography in Liver Cancer Diagnosis and Staging Applications
Primary liver cancer is one of the most common malignant tumor and leading cause of cancer-related death worldwide. Basically therapeutic strategies were considered and given based on the staging of liver cancer.
- Trial name
- RDSA (NCT02936856)
- Testing
- Hepatic Arteriography
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma, Liver Cancer
First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer
MNA-3521-011 study is a multi-centre, open-label, first-in-human, phase 1a/b clinical study dose/dose frequency escalation followed by a cohort expansion part.
- Trial name
- OUTREACH (NCT02716012)
- Testing
- MTL-CEBPA, Sorafenib 200mg
- Where
- 11 sites in Singapore, Taiwan and 1 more
- Volunteers
- 75 people
- Sponsor
- Mina Alpha Limited
Solid Tumors, Soft Tissue Sarcoma
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
This is a pilot study of LTLD with MR-HIFU hyperthermia followed by ablation in subjects with refractory/relapsed solid tumors.
- Conditions
- Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm
- Trial name
- NCT04791228
- Testing
- Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin
- Where
- United States
- Sponsor
- Children's National Research Institute
Carcinoma, Hepatocellular
Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib
This study will collect data of patients who are treated with TACE followed by sorafenib for hepatocellular carcinoma (HCC) or patients without Sorafenib after TACE.
- Trial name
- OPTIMIS (NCT01933945)
- Testing
- TACE (transarterial chemoembolization), Sorafenib (Nexavar, BAY43-9006)
- Where
- 31 sites in Austria, Brazil and 29 more
- Volunteers
- 1,676 people
- Sponsor
- Bayer
Dysplastic Nodule
Role of Early API in Accurately Differentiating Hepatocellular Carcinoma From Dysplastic Nodules in Cirrhotic Patients
Liver cirrhosis is a common consequence of chronic liver disease, resulting from sustained hepatic injury due to various etiologies.
- Trial name
- NCT07080372
- Testing
- assesment
- Where
- Pakistan
- Volunteers
- 73 people
- Sponsor
- Superior University
Rupture, Spontaneous, Rupture Liver
Management of Spontaneous Ruptured Hepatocellular Carcinoma
To investigate the best treatment for hepatocellular carcinoma rupture
- Conditions
- Rupture, Spontaneous, Rupture Liver, Hepatocellular Carcinoma
- Trial name
- NCT03516890
- Testing
- Partial hepatectomy
- Volunteers
- 216 people
- Sponsor
- Huazhong University of Science and Technology
Hepatocellular Carcinoma, Hepatocellular Cancer
Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma
Background: Fibrolamellar Hepatocellular Carcinoma (FL-HCC) is a rare liver cancer. It usually occurs in young people who have no history of liver disease.
- Trial name
- NCT03748927
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Liver Decompensation, Hepatocellular Carcinoma
The Second Multicenter Hemophilia Cohort Study
The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV).
- Conditions
- Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT00341705
- Where
- 48 sites in United States, Brazil and 6 more
- Volunteers
- 2,565 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these.
- Trial name
- NCT00911196
- Testing
- Retrospective analysis of already archived samples
- Where
- 3 sites in Taiwan, Thailand
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Hepatocellular Carcinoma
Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma
Assessment of short-term outcomes of ipsilateral lobe arterial devascularization of the large hepatocellular carcinoma: single center non-randomized trial.
- Trial name
- NRU (NCT03129685)
- Testing
- HALED
- Where
- Sudan
- Volunteers
- 12 people
- Sponsor
- The National Ribat University
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Meningioma
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with cancer that involves taking white blood cells from the patient, growing them in the laboratory in…
- Conditions
- Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT01967823
- Testing
- Anti-NY ESO-1 mTCR PBL, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid
Liver cancer is the sixth most common malignant tumor worldwide and the third leading cause of cancer-related deaths. China is a high-risk area for liver cancer, accounting for approximately 55% of primary liver cancer worldwide.
- Trial name
- NCT06699524
- Testing
- in vitro （chemotherapy）, Adjuvant TACE（Adjuvant Transarterial Chemoembolization）
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Shen Feng